David A Fraser

List of Publications by Year
in descending order

9 papers	130 citations	1477746 6 h-index	1588620 8 g-index
9 all docs	9 docs citations	9 times ranked	250 citing authors

#	Article	IF	Citations
1	A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH. Journal of Hepatology, 2022, 76, 800-811.	1.8	15
2	Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. Liver International, 2020, 40, 2860-2876.	1.9	12
3	Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. Hepatology Communications, 2020, 4, 193-207.	2.0	15
4	LBP-10-A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALTand gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH. Journal of Hepatology, 2019, 70, e145-e146.	1.8	1
5	SAT-346-Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH. Journal of Hepatology, 2019, 70, e791.	1.8	2
6	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. Cardiology, 2016, 135, 3-12.	0.6	11
7	The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients With Type 1 Diabetes. Diabetes Care, 2012, 35, 1095-1097.	4.3	53
8	Polymorphisms in an interferonâ€Î³ receptorâ€1 gene marker and susceptibility to periodontitis*. Acta Odontologica Scandinavica, 2003, 61, 297-302.	0.9	19
9	Structurallyâ€engineered fatty acid 1024 (<scp>SEFA</scp> â€1024) improves dietâ€induced obesity, insulin resistance, and fatty liver disease. Lipids, 0, , .	0.7	2